PR Newswire Clinical TrialsOriginal article
Cumulus Neuroscience Announces Publication in Scientific Reports Demonstrating the NeuLogiq® Platform Is Feasible and Usable for At-Home, Multimodal Cognitive Assessment in People Living with ALS and FTD
Data ReadoutpositiveNeuLogiqPositive
AI Analysis
Summary
Cumulus Neuroscience announced publication of CNS-102 study results in Scientific Reports demonstrating that its NeuLogiq platform is feasible and usable for at-home cognitive assessment in patients with ALS and FTD, with high usability ratings from participants.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
CNS-102 study results published in Scientific Reports demonstrating feasibility and usability of NeuLogiq platform for at-home multimodal cognitive assessment. 82% of ALS participants rated platform easy to use, 75% rating positive (specific metric unclear from excerpt).
Importance:5/10
Sentiment:
0.65
Cumulus NeuroscienceNeuLogiqALSFTDcognitive assessmentpublicationClinical trialat-home monitoring
Read the original article
Published by PR Newswire Clinical Trials on August 18, 2026 3:44 PM